社区获得性细菌性肺炎治疗药物lefamulin的研究进展  

Advances in the study of lefamulin for the treatment of community-acquired bacterial pneumonia

作　　者：张春晓 卢芳 张临 李琳[1] 孙菲菲 Zhang Chun-xiao;Lu Fang;Zhang Lin;Li Lin;Sun Fei-fei(College of Animal Science and Technology,Anhui Agricultural University,Hefei 230036)

机构地区：[1]安徽农业大学动物科技学院,合肥230036

出　　处：《中国抗生素杂志》2022年第10期1020-1024,共5页Chinese Journal of Antibiotics

基　　金：安徽省自然科学基金(No.2008085QC151)。

摘　　要：Lefamulin是首个可以用于治疗全身感染的半合成截短侧耳素类药物。目前,已经完成了lefamulin治疗社区获得性细菌性肺炎(CABP)的Ⅲ期临床试验和急性细菌性皮肤和皮肤结构感染的Ⅱ期临床试验,结果证实了其有效性和安全性,被FDA和EMA批准用于治疗CABP,可经口服和静脉给药。Lefamulin对引起CABP的细菌抗菌谱广,作用机制独特,耐药性出现较慢,与其他抗生素无交叉耐药性。本文从lefamulin的药效学、药动学、临床应用、安全性及耐药机制等方面进行综述,以期为临床合理使用该抗菌素提供理论依据。Lefamulin is the first semi-synthetic pleuromutilin antibiotic to treat systematic infection.It was approved by the FDA and EMA for the treatment of community-acquired bacterial pneumonia(CABP),which can be administered orally and intravenously.The phase III clinical trials for CABP and a phase II clinical trial of acute bacterial skin and skin structure infections have been investigated.The results verified the efficacy and safety of lefamulin.Lefamulin has a broad-spectrum antibacterial effects on CABP-causing bacteria,with a special mechanism of action,slow development of drug resistance,and no cross-resistance with other antibiotics.In this paper,the pharmacodynamics,pharmacokinetics,clinical application,safety,and drug resistance mechanism of lefamulin were reviewed to provide the theoretical basis for the establishment of scientific regime.

关 键 词：Lefamulin 药效学 药动学 临床应用 耐药机制 

分 类 号：R978.1[医药卫生—药品]